June 12, 2018

Dear Local Education Agency Allergy Management Liaison:

We want to share with you a statement from Mylan and BioRidge Pharma, who operates the EpiPen4Schools® Program. As you are aware, this program is a component of the Access to Epinephrine in Schools Act that ensures free auto-injectors are provided to our schools. Given the latest communication from Mylan indicating delays to the timely provision of materials, we are encouraging you to submit your requests for your schools’ respective orders be submitted early. Please see below for Mylan’s statement.

Dear EpiPen4Schools® Program Participant:

We want to let you know that on May 9, 2018, the US Food and Drug Administration (FDA) posted a supply notification about EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, on its website to provide greater transparency and confirm that the product remains available.

As the website posting states, there are intermittent supply constraints; however, product is available and Mylan is currently receiving continual supply from its manufacturing partner Meridian Medical Technologies, a Pfizer company. Mylan is expediting shipment upon receipt, and supply levels may vary across wholesalers and pharmacies.

Mylan and Pfizer take the supply of EpiPen and EpiPen Jr Auto-Injectors very seriously. Pfizer manufactures both the branded and authorized generic versions and Mylan is the distributor.

Mylan is Continuing to Support the EpiPen4Schools® Program

Given the intermittent supply constraints of EpiPen Auto-Injector 0.3 mg, EpiPen Jr 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, there may be delays in order fulfillment for the EpiPen4Schools program until supply levels stabilize. BioRidge Pharma is a specialty distributor of biotech products and facilitates the certification and fulfillment of all EpiPen4Schools orders.

Thank you,

Mylan and BioRidge Pharma
If you have questions regarding this or other matters related to the epi-pen program, please email OSSE.EPI@dc.gov or complete the Technical Assistance form linked here. Please allow 48 hours for the team to follow up on any inquiries.

Sincerely,
OSSE Allergy Management Team